Inositol trisphosphate

1D-myo-inositol 1,4,5-triphosphate

The inositol trisphosphate trianion
Names
IUPAC name (1R,2R,3S,4R,5R,6S)-3,5,6-Trihydroxy-1,2,4-cyclohexanetriyl tris[dihydrogen (phosphate)]
Other names IP3; Triphosphoinositol; Inositol 1,4,5-trisphosphate
Identifiers
CAS Number	85166-31-0
ChemSpider	388562
IUPHAR/BPS	4222
Jmol interactive 3D	Image
PubChem	439456
InChI InChI=1S/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2+,3+,4-,5-,6-/m1/s1 Key: MMWCIQZXVOZEGG-XJTPDSDZSA-N InChI=1/C6H15O15P3/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)/t1-,2+,3+,4-,5-,6-/m1/s1 Key: MMWCIQZXVOZEGG-XJTPDSDZBF
SMILES [C@H]1([C@@H]([C@H]([C@@H]([C@H]([C@@H]1OP(=O)(O)O)O)OP(=O)(O)O)OP(=O)(O)O)O)O
Properties
Chemical formula	C6H15O15P3
Molar mass	420.096 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Inositol trisphosphate or inositol 1,4,5-trisphosphate (also commonly known as triphosphoinositol; abbreviated InsP₃ or Ins3P or IP₃), together with diacylglycerol (DAG), is a secondary messenger molecule used in signal transduction and lipid signaling in biological cells. While DAG stays inside the membrane, IP₃ is soluble and diffuses through the cell. It is made by hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP₂), a phospholipid that is located in the plasma membrane, by phospholipase C (PLC).

Properties

Chemical formula and molecular weight

IP₃ is an organic molecule with a molecular mass of 420.10 g/mol. Its empirical formula is C₆H₁₅O₁₅P₃. It is composed of an inositol ring with three phosphate groups bound at the 1, 4, and 5 carbon positions, and three hydroxyl groups bound at positions 2, 3, and 6.^[1]

Chemical properties

Phosphate groups can exist in three different forms depending on a solution's pH. Phosphorus atoms can bind three oxygen atoms with single bonds and a fourth oxygen atom using a double/dative bond. The pH of the solution, and thus the form of the phosphate group determines its ability to bind to other molecules. The binding of phosphate groups to the inositol ring is accomplished by phosphor-ester binding (see phosphoric acids and phosphates). This bond involves combining a hydroxyl group from the inositol ring and a free phosphate group through a dehydration reaction. Considering that the average physiological pH is approximately 7.4, the main form of the phosphate groups bound to the inositol ring in vivo is PO₄²⁻. This gives IP₃ a net negative charge, which is important in allowing it to dock to its receptor, through binding of the phosphate groups to positively charged residues on the receptor. IP₃ has three hydrogen bond donors in the form of its three hydroxyl groups. The hydroxyl group on the 6th carbon atom in the inositol ring is also involved in IP₃ docking.^[2]

Binding to its receptor

IP₃ anion with oxygen atoms(red) and the hydrogen atoms(dark blue) involved in docking to the InsP3R labelled

The docking of IP₃ to its receptor, which is called the inositol trisphosphate receptor (InsP3R), was first studied using deletion mutagenesis in the early 1990s.^[3] Studies focused on the N-terminus side of the IP₃ receptor. In 1997 researchers localized the region of the IP₃ receptor involved with binding of IP₃ to between amino acid residues 226 and 578 in 1997. Considering that IP₃ is a negatively charged molecule, positively charged amino acids such as arginine and lysine were believed to be involved. Two arginine residues at position 265 and 511 and one lysine residue at position 508 were found to be key in IP₃ docking. Using a modified form of IP₃, it was discovered that all three phosphate groups interact with the receptor, but not equally. Phosphates at the 4th and 5th positions interact more extensively than the phosphate at the 1st position and the hydroxyl group at the 6th position of the inositol ring.^[4]

Discovery

The discovery that a hormone can influence phosphoinositide metabolism was made by Mabel R. Hokin (1924–2003) and her then husband Lowell E. Hokin in 1953, when they discovered that radioactive ³²P phosphate was incorporated into the phosphatidylinositol of pancreas slices when stimulated with acetylcholine. Up until then phospholipids were believed to be innate structures only used by cells as building blocks for construction of the plasma membrane.^[5]

Over the next 20 years, little was discovered about the importance of PIP₂ metabolism in terms of cell signaling, until the mid-1970s when Robert H. Michell hypothesized a connection between the catabolism of PIP₂ and increases in intracellular calcium (Ca²⁺) levels. He hypothesized that receptor-activated hydrolysis of PIP₂ produced a molecule that caused increases in intracellular calcium mobilization.^[6] This idea was researched extensively by Michell and his colleagues, who in 1981 were able to show that PIP₂ is hydrolyzed into DAG and IP₃ by a then unknown phosphodiesterase. In 1984 it was discovered that IP₃ acts as a secondary messenger that is capable of traveling through the cytoplasm to the endoplasmic reticulum (ER), where it stimulates the release of calcium into the cytoplasm.^[7]

Further research provided valuable information on the IP₃ pathway, such as the discovery in 1986 that one of the many roles of the calcium released by IP₃ is to work with DAG to activate protein kinase C (PKC).^[8] It was discovered in 1989 that phospholipase C (PLC) is the phosphodiesterase responsible for hydrolyzing PIP₂ into DAG and IP₃.^[9] Today the IP₃ signaling pathway is well mapped out, and is known to be important in regulating a variety of calcium-dependent cell signaling pathways.

Signaling pathway

PLC cleavage of PIP₂ to IP₃ and DAG initiates intracellular calcium release and PKC activation.

Increases in the intracellular Ca²⁺ concentrations are often a result of IP₃ activation. When a ligand binds to a G protein-coupled receptor (GPCR) that is coupled to a Gq heterotrimeric G protein, the α-subunit of Gq can bind to and induce activity in the PLC isozyme PLC-β, which results in the cleavage of PIP₂ into IP₃ and DAG.^[10]

If a receptor tyrosine kinase (RTK) is involved in activating the pathway, the isozyme PLC-γ has tyrosine residues that can become phosphorylated upon activation of an RTK, and this will activate PLC-γ and allow it to cleave PIP₂ into DAG and IP₃. This occurs in cells that are capable of responding to growth factors such as insulin, because the growth factors are the ligands responsible for activating the RTK.^[11]

IP₃ (also abbreviated Ins3P) is a soluble molecule and is capable of diffusing through the cytoplasm to the ER, or the sarcoplasmic reticulum (SR) in the case of muscle cells, once it has been produced by the action of PLC. Once at the ER, IP₃ is able to bind to the Ins3P receptor (Ins3PR) on a ligand-gated Ca²⁺ channel that is found on the surface of the ER. The binding of IP3 (the ligand in this case) to InsP3R triggers the opening of the Ca²⁺ channel, and thus release of Ca²⁺ into the cytoplasm.^[11] In heart muscle cells this increase in Ca²⁺ activates the ryanodine receptor-operated channel on the SR, results in further increases in Ca²⁺ through a process known as calcium-induced calcium release. IP₃ may also activate Ca²⁺ channels on the cell membrane indirectly, by increasing the intracellular Ca²⁺ concentration.^[10]

Function

Human

IP₃'s main functions are to mobilize Ca²⁺ from storage organelles and to regulate cell proliferation and other cellular reactions that require free calcium. (In smooth muscle cells, for example, an increase in concentration of cytoplasmic Ca²⁺ results in the contraction of the muscle cell.)^[12]

In the nervous system, IP₃ serves as a second messenger, with the cerebellum containing the highest concentration of IP₃ receptors.^[13] There is evidence that IP₃ receptors play an important role in the induction of plasticity in cerebellar Purkinje cells.^[14]

Sea urchin eggs

The slow block to polyspermy in the sea urchin is mediated by the PIP₂ secondary messenger system. Activation of the binding receptors activates PLC, which cleaves PIP₂ in the egg plasma membrane, releasing IP₃ into the egg cell cytoplasm. IP₃ diffuses to the ER, where it opens Ca²⁺ channels.

Relation to disease

Huntington's disease

Huntington's disease is an incurable genetic disorder that occurs when neurons in the brain degenerate.^[15] Huntington's disease primarily affects striatal medium spiny neurons (MSN).^[16] GABAergic MSNs make up more than 95% of all neurons in the striatum.^[17] Huntington's disease occurs when the cytosolic protein Huntingtin (Htt) has an additional 35 glutamine residues added to its amino terminal region. This modified form of Htt is called Htt^exp. Htt^exp makes Type 1 IP₃ receptors more sensitive to IP₃, which leads to the release of too much Ca²⁺ from the ER. The release of Ca²⁺ from the ER causes an increase in the cytosolic and mitochondrial concentrations of Ca²⁺. This increase in Ca²⁺ is thought to be the cause of GABAergic MSN degradation ^[16]

Alzheimer's disease

Alzheimer's disease involves the progressive degeneration of the brain, severely impacting mental faculties.^[18] Since the Ca²⁺ hypothesis of Alzheimer's was proposed in 1994, several studies have shown that disruptions in Ca²⁺ signaling are the primary cause of Alzheimer's disease. Familial Alzheimer's disease has been strongly linked to mutations in the presenilin 1 (PS1), presenilin 2 (PS2), and amyloid precursor protein (APP) genes. All of the mutated forms of these genes observed to date have been found to cause abnormal Ca²⁺ signaling in the ER. The functions of PS1 are not yet known, but mutations in PS1 have been shown to increase IP₃-mediated Ca²⁺ release from the ER in several animal models. Calcium channel blockers have been used to treat Alzheimer's disease with some success, and the use of lithium to decrease IP₃ turnover has also been suggested as a possible method of treatment.^[19]

See also

• Inositol
• Inositol phosphate
• myo-Inositol
• Inositol pentakisphosphate
• Inositol hexaphosphate
• Inositol trisphosphate receptor
• ITPR1
• ITPKC

References

External links

• Inositol 1,4,5-Trisphosphate at the US National Library of Medicine Medical Subject Headings (MeSH)